Telix, Varian announce strategic collaboration to develop theranostics-EBRT

Telix Pharmaceuticals (TLX) announces a strategic clinical collaboration with Varian, a Siemens Healthineers (SMMNY) company, to develop novel clinical applications that combine Telix’s theranostic products and external beam radiation therapy, EBRT. Dr. Christian Behrenbruch, Group CEO and Managing Director, Telix, said, “This strategic partnership with Varian represents a transformative opportunity to bring precision imaging into the heart of radiation oncology. Integrating theranostics into EBRT has the potential to improve patient outcomes. And by combining Telix’s innovation in molecular imaging with Varian’s global leadership in cancer treatment technologies, we are building alliances to explore new frontiers in personalized cancer care.”